Recruiting
Renal cell carcinoma
RecruitingStudy on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients
Registered drugNo placebo
Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients
Registered drugNo placebo
- Disease:Renal cell carcinoma
- Substances:AxitinibCabozantinib+4
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Axitinib
- Sponsor:Institut Gustave Roussy



